Teriflunomide  ||| S:0 E:14 ||| NNP
for  ||| S:14 E:18 ||| IN
the  ||| S:18 E:22 ||| DT
treatment  ||| S:22 E:32 ||| NN
of  ||| S:32 E:35 ||| IN
multiple  ||| S:35 E:44 ||| JJ
sclerosis  ||| S:44 E:54 ||| JJ
Teriflunomide  ||| S:54 E:68 ||| NNP
is  ||| S:68 E:71 ||| VBZ
a  ||| S:71 E:73 ||| DT
new  ||| S:73 E:77 ||| JJ
active  ||| S:77 E:84 ||| JJ
drug  ||| S:84 E:89 ||| NN
which  ||| S:89 E:95 ||| WDT
has  ||| S:95 E:99 ||| VBZ
recently  ||| S:99 E:108 ||| RB
been  ||| S:108 E:113 ||| VBN
approved  ||| S:113 E:122 ||| VBN
as  ||| S:122 E:125 ||| IN
a  ||| S:125 E:127 ||| DT
first-line  ||| S:127 E:138 ||| JJ
treatment  ||| S:138 E:148 ||| NN
of  ||| S:148 E:151 ||| IN
relapsing  ||| S:151 E:161 ||| JJ
forms  ||| S:161 E:167 ||| NNS
of  ||| S:167 E:170 ||| IN
MS  ||| S:170 E:173 ||| NNP
in  ||| S:173 E:176 ||| IN
the  ||| S:176 E:180 ||| DT
US ||| S:180 E:182 ||| NNP
,  ||| S:182 E:184 ||| ,
Australia ||| S:184 E:193 ||| NNP
,  ||| S:193 E:195 ||| ,
Argentina ||| S:195 E:204 ||| NNP
,  ||| S:204 E:206 ||| ,
and  ||| S:206 E:210 ||| CC
the  ||| S:210 E:214 ||| DT
European  ||| S:214 E:223 ||| NNP
Union ||| S:223 E:228 ||| NNP
.  ||| S:228 E:230 ||| .
It  ||| S:230 E:233 ||| PRP
is  ||| S:233 E:236 ||| VBZ
characterized  ||| S:236 E:250 ||| VBN
by  ||| S:250 E:253 ||| IN
a  ||| S:253 E:255 ||| DT
once-daily  ||| S:255 E:266 ||| JJ
oral  ||| S:266 E:271 ||| JJ
application  ||| S:271 E:283 ||| NN
and  ||| S:283 E:287 ||| CC
a  ||| S:287 E:289 ||| DT
well-established  ||| S:289 E:306 ||| JJ
long-term  ||| S:306 E:316 ||| JJ
safety  ||| S:316 E:323 ||| NN
profile ||| S:323 E:330 ||| NN
.  ||| S:330 E:332 ||| .
The  ||| S:332 E:336 ||| DT
main  ||| S:336 E:341 ||| JJ
therapeutic  ||| S:341 E:353 ||| JJ
effect  ||| S:353 E:360 ||| NN
is  ||| S:360 E:363 ||| VBZ
considered  ||| S:363 E:374 ||| VBN
to  ||| S:374 E:377 ||| TO
be  ||| S:377 E:380 ||| VB
mediated  ||| S:380 E:389 ||| VBN
via  ||| S:389 E:393 ||| IN
the  ||| S:393 E:397 ||| DT
inhibition  ||| S:397 E:408 ||| NN
of  ||| S:408 E:411 ||| IN
the  ||| S:411 E:415 ||| DT
de  ||| S:415 E:418 ||| FW
novo  ||| S:418 E:423 ||| FW
synthesis  ||| S:423 E:433 ||| FW
of  ||| S:433 E:436 ||| IN
pyrimidine  ||| S:436 E:447 ||| NN
in  ||| S:447 E:450 ||| IN
proliferating  ||| S:450 E:464 ||| VBG
immune  ||| S:464 E:471 ||| JJ
cells ||| S:471 E:476 ||| NNS
.  ||| S:476 E:478 ||| .
Two  ||| S:478 E:482 ||| CD
phase  ||| S:482 E:488 ||| NN
III  ||| S:488 E:492 ||| NNP
clinical  ||| S:492 E:501 ||| JJ
trials  ||| S:501 E:508 ||| NNS
( ||| S:508 E:509 ||| -LRB-
TEMSO ||| S:509 E:514 ||| NNP
,  ||| S:514 E:516 ||| ,
TOWER ||| S:516 E:521 ||| NNP
)  ||| S:521 E:523 ||| -RRB-
tested  ||| S:523 E:530 ||| VBD
teriflunomide  ||| S:530 E:544 ||| VBN
in  ||| S:544 E:547 ||| IN
patients  ||| S:547 E:556 ||| NNS
with  ||| S:556 E:561 ||| IN
relapsing  ||| S:561 E:571 ||| JJ
forms  ||| S:571 E:577 ||| NNS
of  ||| S:577 E:580 ||| IN
MS ||| S:580 E:582 ||| NNP
:  ||| S:582 E:584 ||| :
efficacy  ||| S:584 E:593 ||| NNS
was  ||| S:593 E:597 ||| VBD
shown ||| S:597 E:602 ||| VBN
,  ||| S:602 E:604 ||| ,
with  ||| S:604 E:609 ||| IN
positive  ||| S:609 E:618 ||| JJ
effects  ||| S:618 E:626 ||| NNS
on  ||| S:626 E:629 ||| IN
relapse  ||| S:629 E:637 ||| JJ
rates  ||| S:637 E:643 ||| NNS
and  ||| S:643 E:647 ||| CC
disease  ||| S:647 E:655 ||| NN
progression  ||| S:655 E:667 ||| NN
for  ||| S:667 E:671 ||| IN
14  ||| S:671 E:674 ||| CD
mg ||| S:674 E:676 ||| CD
/ ||| S:676 E:677 ||| CD
day ||| S:677 E:680 ||| NN
.  ||| S:680 E:682 ||| .
Overall ||| S:682 E:689 ||| RB
,  ||| S:689 E:691 ||| ,
the  ||| S:691 E:695 ||| DT
safety  ||| S:695 E:702 ||| NN
profile  ||| S:702 E:710 ||| NN
in  ||| S:710 E:713 ||| IN
these  ||| S:713 E:719 ||| DT
studies  ||| S:719 E:727 ||| NNS
was  ||| S:727 E:731 ||| VBD
favorable ||| S:731 E:740 ||| JJ
.  ||| S:740 E:742 ||| .
In  ||| S:742 E:745 ||| IN
patients  ||| S:745 E:754 ||| NNS
treated  ||| S:754 E:762 ||| VBN
with  ||| S:762 E:767 ||| IN
teriflunomide ||| S:767 E:780 ||| NN
,  ||| S:780 E:782 ||| ,
the  ||| S:782 E:786 ||| DT
regular  ||| S:786 E:794 ||| JJ
monitoring  ||| S:794 E:805 ||| NN
of  ||| S:805 E:808 ||| IN
blood  ||| S:808 E:814 ||| NN
cell  ||| S:814 E:819 ||| NN
counts  ||| S:819 E:826 ||| NNS
and  ||| S:826 E:830 ||| CC
liver  ||| S:830 E:836 ||| JJ
enzymes  ||| S:836 E:844 ||| NN
is  ||| S:844 E:847 ||| VBZ
required ||| S:847 E:855 ||| VBN
.  ||| S:855 E:857 ||| .
Teriflunomide  ||| S:857 E:871 ||| NNP
must  ||| S:871 E:876 ||| MD
not  ||| S:876 E:880 ||| RB
be  ||| S:880 E:883 ||| VB
used  ||| S:883 E:888 ||| VBN
during  ||| S:888 E:895 ||| IN
pregnancy ||| S:895 E:904 ||| NN
.  ||| S:904 E:906 ||| .
In  ||| S:906 E:909 ||| IN
this  ||| S:909 E:914 ||| DT
article ||| S:914 E:921 ||| NN
,  ||| S:921 E:923 ||| ,
we  ||| S:923 E:926 ||| PRP
review  ||| S:926 E:933 ||| VBP
recent  ||| S:933 E:940 ||| JJ
phase  ||| S:940 E:946 ||| NN
II  ||| S:946 E:949 ||| NNP
and  ||| S:949 E:953 ||| CC
phase  ||| S:953 E:959 ||| NN
III  ||| S:959 E:963 ||| NNP
clinical  ||| S:963 E:972 ||| JJ
trial  ||| S:972 E:978 ||| NN
data ||| S:978 E:982 ||| NNS
,  ||| S:982 E:984 ||| ,
and  ||| S:984 E:988 ||| CC
discuss  ||| S:988 E:996 ||| VB
the  ||| S:996 E:1000 ||| DT
potential  ||| S:1000 E:1010 ||| NN
of  ||| S:1010 E:1013 ||| IN
teriflunomide  ||| S:1013 E:1027 ||| NN
for  ||| S:1027 E:1031 ||| IN
the  ||| S:1031 E:1035 ||| DT
treatment  ||| S:1035 E:1045 ||| NN
of  ||| S:1045 E:1048 ||| IN
relapsing  ||| S:1048 E:1058 ||| JJ
forms  ||| S:1058 E:1064 ||| NNS
of  ||| S:1064 E:1067 ||| IN
MS ||| S:1067 E:1069 ||| NNP
.  ||| S:1069 E:1071 ||| .
